Phase II Study of Pimavanserin in Alzheimer's Disease Agitation.

Trial Profile

Phase II Study of Pimavanserin in Alzheimer's Disease Agitation.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Pimavanserin (Primary)
  • Indications Agitation
  • Focus Therapeutic Use
  • Acronyms SERENE
  • Sponsors Acadia Pharmaceuticals
  • Most Recent Events

    • 04 Oct 2017 According to a company media release, ACADIA announced that due to the potential overlap of clinical sites and study participants between its Phase III HARMONY dementia-related psychosis study and this trial of pimavanserin in Alzheimer's disease agitation, it has decided to discontinue enrollment of new patients in the SERENE study. Patients already enrolled will complete the study as planned.
    • 04 Oct 2017 Status changed from recruiting to discontinued, according to an Acadia Pharmaceuticals media release.
    • 12 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top